心脏骤停自主循环恢复后初始去甲肾上腺素与肾上腺素血流动力学支持的临床结局比较
该回顾性研究纳入93例心脏骤停自主循环恢复后在急诊科接受血管升压药的患者,其中去甲肾上腺素组45例、肾上腺素组42例、多巴胺组6例(因样本量小未纳入事后分析)。肾上腺素组在急诊科内达到主要终点(难治性低血压、再停搏或死亡)的比例显著高于去甲肾上腺素组(50% vs 22.2%,P=0.008);在6小时早期复苏期(71.4% vs 55.6%,P=0.182)和整个住院期间(95.2% vs 80.0%,P=0.051)差异不再显著。校正血管升压药启动前再停搏后,肾上腺素组在急诊科达到主要终点的比值比是去甲肾上腺素组的3.94倍(95%CI 1.38-12.2,P=0.013)。两组快速性心律失常和出院时功能状态无差异。作者认为这些结果提示可能需要前瞻性研究,但回顾性设计无法控制潜在混杂因素限制了结论。
要点
- 急诊科内主要终点(难治性低血压、再停搏或死亡):肾上腺素组21/42(50%)vs 去甲肾上腺素组10/45(22.2%),P=0.008。
- 校正血管升压药启动前再停搏后,肾上腺素组急诊科达到主要终点的比值比为3.94(95%CI 1.38-12.2),P=0.013。
- 6小时早期复苏期主要终点:肾上腺素组30/42(71.4%)vs 去甲肾上腺素组25/45(55.6%),P=0.182,差异不显著。
- 整个住院期间主要终点:肾上腺素组40/42(95.2%)vs 去甲肾上腺素组36/45(80.0%),P=0.051,差异未达统计学显著。
- 两组快速性心律失常和出院时功能状态无差异;多巴胺组仅6例,因样本量小未纳入事后分析。
适用人群与场景
- 在急诊科因院外心脏骤停或急诊科内心脏骤停达到自主循环恢复后接受血管升压药的患者。
- 三级学术医疗中心32个月期间的电子病历回顾性分析。
诊断标准与关键阈值
- 纳入标准:院外心脏骤停或急诊科内心脏骤停达到自主循环恢复后,在急诊科接受血管升压药的患者。
研究设计与关键结果
- 研究类型:单中心回顾性电子病历审查;样本量93例;去甲肾上腺素组45例、肾上腺素组42例、多巴胺组6例。
- 主要终点为急诊科内难治性低血压、再停搏或死亡:肾上腺素组21/42(50%)vs 去甲肾上腺素组10/45(22.2%),P=0.008。
- 6小时早期复苏期主要终点:肾上腺素组30/42(71.4%)vs 去甲肾上腺素组25/45(55.6%),P=0.182。
- 整个住院期间主要终点:肾上腺素组40/42(95.2%)vs 去甲肾上腺素组36/45(80.0%),P=0.051。
- 校正血管升压药启动前再停搏的回归模型中,肾上腺素组急诊科达到主要终点的比值比为3.94(95%CI 1.38-12.2),P=0.013,高于去甲肾上腺素组。
- 肾上腺素组血管升压药启动前再停搏率更高,可能提示病情更重,尽管其他预后变量分布相似。
- 两组快速性心律失常和出院时功能状态(出院回家无需帮助,或出院至长期护理机构、亚急性康复机构或辅助生活机构)无差异。
证据类型、等级与局限
- 证据类型:单中心回顾性研究。
- 作者指出回顾性研究无法控制潜在混杂变量,限制了研究发现;结果为假设生成性,需要进一步研究。
对床旁实践的改变
- 作者认为这些数据提示可能有必要对自主循环恢复后用于血流动力学支持的初始血管升压药进行前瞻性研究。
- 作者指出在该人群中,肾上腺素治疗患者的急诊科内难治性休克、再停搏或死亡率高于去甲肾上腺素治疗患者,但回顾性设计无法控制潜在混杂变量限制了这些发现,结果属假设生成性。
指南或共识出处
- 高级心脏生命支持指南推荐在自主循环恢复后启动去甲肾上腺素、肾上腺素或多巴胺以维持足够血流动力学。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The optimal vasoactive agent for management of patients with return of spontaneous circulation (ROSC) after cardiac arrest has not yet been identified. The Advanced Cardiac Life Support guidelines recommend initiation of either norepinephrine (NE), epinephrine (EPI), or dopamine (DA) to maintain adequate hemodynamics after ROSC is achieved. The goal of this study is to retrospectively assess the impact of initial vasopressor agent on incidence rate of rearrest, death, or need for additional vasopressor in post-cardiac arrest emergency department (ED) patients.
METHODS: A retrospective review of electronic medical records was conducted at a tertiary care, academic medical center over a 32-month period. Inclusion criteria were any patient who received vasopressors in the ED after achieving ROSC from out-of-hospital cardiac arrest, or in ED cardiac arrest. The incidence of the primary outcome was assessed during care within the ED, at 6 h regardless of location (early resuscitation period), and throughout the entire hospitalization. Secondary outcomes included incidence of tachyarrhythmia while on vasopressor, type of additional therapy needed for refractory shock, and functional status at discharge as determined by discharge location (discharged home without assistance, or discharged to long-term care facility, subacute rehabilitation, or assisted living).
RESULTS: A total of 93 patients were included for analysis; 45 received NE, 42 EPI, and six DA. Due to small sample size, DA was excluded from reporting post hoc. Significantly more EPI patients met the primary outcome of refractory hypotension, rearrest, or death in the emergency department (EPI 21/42, 50% vs. NE 10/45, 22.2%; P = 0.008). The incidence was no longer significantly different during the early resuscitation period of 6 h (EPI 30/42, 71.4% vs. NE 25/45, 55.6%; P = 0.182), or during the entire hospitalization (EPI 40/42, 95.2% vs. NE 36/45, 80.0%; P = 0.051). Notably, the EPI group had higher rates of rearrest prior to vasopressor initiation, potentially signaling more severe illness despite other prognostic variables being similarly distributed. In an adjusted regression model, which included adjustment for rearrest prior to vasopressor initiation, the odds of reaching the primary outcome in the ED were 3.94 [95%CI 1.38-12.2] (P = 0.013) times higher in the EPI group compared to NE treated patients. No difference in tachyarrhythmia or functional status at discharge was detected between groups.
CONCLUSION: These data suggest prospective study of initial vasopressors used for hemodynamic support after ROSC may be warranted. Rates of intra-emergency department refractory shock, rearrest, or death were higher among epinephrine treated patients compared to norepinephrine treated patients in this population. However, inability to control for potential confounding variables in retrospective studies limits the findings. These results are hypothesis generating and further study is warranted.
参考来源
- Weiss A, Dang C, Mabrey D, et al. Comparison of Clinical Outcomes with Initial Norepinephrine or Epinephrine for Hemodynamic Support After Return of Spontaneous Circulation. Shock. 2021. PMID: 34172611. doi:10.1097/SHK.0000000000001830
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。